United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Wedbush raised their FY2022 earnings estimates for shares of United Therapeutics in a research note issued to investors on Monday, April 5th. Wedbush analyst L. Moussatos now expects that the biotechnology company will earn $12.18 per share for the year, up from their prior forecast of $11.59. Wedbush currently has a “Outperform” rating and a $260.00 target price on the stock. Wedbush also issued estimates for United Therapeutics’ Q4 2022 earnings at $2.94 EPS and FY2023 earnings at $16.13 EPS.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Tuesday, February 23rd. The biotechnology company reported $2.19 earnings per share for the quarter, missing analysts’ consensus estimates of $2.96 by ($0.77). The company had revenue of $384.90 million for the quarter, compared to analyst estimates of $362.04 million. United Therapeutics had a net margin of 33.25% and a return on equity of 15.48%. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.96 earnings per share.
NASDAQ:UTHR opened at $191.10 on Thursday. The stock’s fifty day moving average price is $170.31 and its two-hundred day moving average price is $147.53. United Therapeutics has a 52-week low of $94.09 and a 52-week high of $200.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 6.88 and a current ratio of 7.22. The company has a market cap of $8.51 billion, a price-to-earnings ratio of 18.08 and a beta of 0.52.
In other United Therapeutics news, Director Judy D. Olian sold 2,103 shares of the stock in a transaction dated Wednesday, March 17th. The shares were sold at an average price of $170.00, for a total value of $357,510.00. Following the transaction, the director now directly owns 7,893 shares of the company’s stock, valued at approximately $1,341,810. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Judy D. Olian sold 4,207 shares of the stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $184.96, for a total transaction of $778,126.72. Following the completion of the transaction, the director now directly owns 9,997 shares in the company, valued at $1,849,045.12. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in UTHR. Amundi Pioneer Asset Management Inc. raised its holdings in United Therapeutics by 18.8% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company’s stock valued at $8,945,000 after acquiring an additional 12,087 shares during the period. LPL Financial LLC increased its holdings in shares of United Therapeutics by 10.3% during the third quarter. LPL Financial LLC now owns 2,405 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 224 shares during the period. ProShare Advisors LLC increased its holdings in shares of United Therapeutics by 2.5% during the third quarter. ProShare Advisors LLC now owns 10,933 shares of the biotechnology company’s stock worth $1,104,000 after purchasing an additional 265 shares during the period. Morgan Stanley increased its holdings in shares of United Therapeutics by 44.4% during the third quarter. Morgan Stanley now owns 24,455 shares of the biotechnology company’s stock worth $2,469,000 after purchasing an additional 7,525 shares during the period. Finally, Advisors Asset Management Inc. increased its holdings in shares of United Therapeutics by 86.3% during the third quarter. Advisors Asset Management Inc. now owns 1,613 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 747 shares during the period. 90.09% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Article: Does a trade war provide a risk to the global economy?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.